Hofseth BioCare ASA (HOFBF)
USD 0.16
(0.0%)
USD 0.16
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -70.6 Million NOK | -762.61% |
| 2022 | -97.02 Million NOK | 14.05% |
| 2021 | -87.72 Million NOK | -17.28% |
| 2020 | -66.11 Million NOK | -56.43% |
| 2019 | -61.65 Million NOK | 88.96% |
| 2018 | -57.5 Million NOK | -31.63% |
| 2017 | -43.68 Million NOK | 63.61% |
| 2016 | -120.05 Million NOK | -21.05% |
| 2015 | -99.17 Million NOK | -117.76% |
| 2014 | -45.54 Million NOK | -26.13% |
| 2013 | -36.1 Million NOK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.06 Million USD | 75.2% |
| 2024 Q1 | -1.61 Million USD | 55.76% |
| 2023 Q3 | -1.61 Million USD | -237.09% |
| 2023 FY | - USD | -762.61% |
| 2023 Q1 | -2.72 Million USD | 5.61% |
| 2023 Q2 | -479.72 Thousand USD | 82.37% |
| 2023 Q4 | -3.9 Million USD | -141.55% |
| 2022 Q3 | -2.33 Million NOK | -26.16% |
| 2022 Q2 | -1.84 Million NOK | 37.86% |
| 2022 FY | - NOK | 14.05% |
| 2022 Q1 | -2.97 Million NOK | -9.37% |
| 2022 Q4 | -2.88 Million NOK | -23.56% |
| 2021 Q4 | -2.72 Million NOK | 18.56% |
| 2021 Q3 | -3.34 Million NOK | -97.43% |
| 2021 FY | - NOK | -17.28% |
| 2021 Q1 | -2.2 Million NOK | 88.74% |
| 2021 Q2 | -1.69 Million NOK | 23.22% |
| 2020 Q4 | -19.57 Million NOK | 18.28% |
| 2020 Q1 | -9.95 Million NOK | 58.33% |
| 2020 FY | - NOK | -56.43% |
| 2020 Q2 | -12.77 Million NOK | -28.23% |
| 2020 Q3 | -23.95 Million NOK | -87.6% |
| 2019 Q4 | -23.9 Million NOK | -160.63% |
| 2019 FY | - NOK | 88.96% |
| 2019 Q3 | -9.17 Million NOK | -14.02% |
| 2019 Q2 | -8.04 Million NOK | 33.37% |
| 2019 Q1 | -12.07 Million NOK | 30.08% |
| 2018 Q3 | -13.56 Million NOK | -8.93% |
| 2018 Q2 | -12.45 Million NOK | 18.18% |
| 2018 Q1 | -15.22 Million NOK | -108.79% |
| 2018 FY | - NOK | -31.63% |
| 2018 Q4 | -17.26 Million NOK | -27.26% |
| 2017 FY | - NOK | 63.61% |
| 2017 Q3 | -6.21 Million NOK | 53.63% |
| 2017 Q1 | 35.43 Million NOK | 434.75% |
| 2017 Q2 | -13.39 Million NOK | -137.8% |
| 2017 Q4 | -7.29 Million NOK | -17.39% |
| 2016 Q4 | -10.58 Million NOK | 70.48% |
| 2016 Q2 | -43.17 Million NOK | -103.89% |
| 2016 Q1 | -21.17 Million NOK | 38.3% |
| 2016 FY | - NOK | -21.05% |
| 2016 Q3 | -35.84 Million NOK | 16.96% |
| 2015 Q4 | -34.31 Million NOK | -274.52% |
| 2015 Q2 | -15.8 Million NOK | -21.59% |
| 2015 Q1 | -12.99 Million NOK | 37.92% |
| 2015 FY | - NOK | -117.76% |
| 2015 Q3 | -9.16 Million NOK | 42.01% |
| 2014 Q1 | -9.5 Million NOK | -12.47% |
| 2014 Q4 | -20.93 Million NOK | -232.55% |
| 2014 Q3 | -6.29 Million NOK | 8.3% |
| 2014 Q2 | -6.86 Million NOK | 27.82% |
| 2014 FY | - NOK | -26.13% |
| 2013 Q4 | -8.45 Million NOK | -131.96% |
| 2013 Q1 | -20.43 Million NOK | -4.19% |
| 2013 Q2 | -10.07 Million NOK | 50.67% |
| 2013 FY | - NOK | 0.0% |
| 2013 Q3 | -3.64 Million NOK | 63.84% |
| 2012 Q3 | -6.46 Million NOK | 36.58% |
| 2012 Q2 | -10.18 Million NOK | 25.97% |
| 2012 Q4 | -19.6 Million NOK | -203.45% |
| 2012 Q1 | -13.76 Million NOK | -137.51% |
| 2011 Q3 | -5.98 Million NOK | -12.24% |
| 2011 Q2 | -5.33 Million NOK | -19.26% |
| 2011 Q1 | -4.47 Million NOK | 41.81% |
| 2011 Q4 | -5.79 Million NOK | 3.25% |
| 2010 Q4 | -7.68 Million NOK | -465.56% |
| 2010 Q3 | -1.35 Million NOK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.37 Million USD | -306.459% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -1717.615% |
| CSL Limited | 4.78 Billion USD | 101.474% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 175.078% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -7435.309% |
| BioStem Technologies, Inc. | -7.55 Million USD | -834.675% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -3934.402% |
| Qrons Inc. | -40.08 Thousand USD | -176048.3% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 13485.966% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -27.581% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -885.886% |
| Skye Bioscience, Inc. | -13.54 Million USD | -421.142% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -19126.025% |
| Rebus Holdings, Inc. | -951 Thousand USD | -7323.975% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -344.884% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -248.71 Million USD | 71.614% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -11064.031% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 0.611% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -1090.809% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -29422.057% |
| SQZ Biotechnologies Company | -64.14 Million USD | -10.073% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -2569.82% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -4496.338% |
| Mesoblast Limited | -62.38 Million USD | -13.163% |
| Marizyme, Inc. | -34.28 Million USD | -105.948% |
| Genus plc | 73.7 Million USD | 195.796% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -967.864% |
| Pharming Group N.V. | 9.87 Million USD | 814.812% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -4646.634% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1890.472% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -704.856% |
| ContraFect Corporation | -64.99 Million USD | -8.62% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -1459.853% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -4936.496% |
| IMV Inc. | -35.52 Million USD | -98.748% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -2938.187% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -13528.519% |
| ONE Bio Corp. | 13.61 Million USD | 618.635% |
| Accustem Sciences Inc. | -3.74 Million USD | -1784.52% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -46.395% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -5471.795% |
| Q BioMed Inc. | -617.62 Thousand USD | -11331.153% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 2076.54% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -2990.494% |
| Biomind Labs Inc. | -1.03 Million USD | -6724.423% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -78.122% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -2341.011% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 1050100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -282308.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -2721.865% |
| GB Sciences, Inc. | -1.41 Million USD | -4872.375% |
| Alpha Cognition Inc. | -9.7 Million USD | -627.436% |
| HST Global, Inc. | -5303.00 USD | -1331259.608% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -3332.28% |
| Halberd Corporation | -74.27 Thousand USD | -94949.745% |
| Enzolytics Inc. | -2.12 Million USD | -3227.099% |
| Agentix Corp. | -1.37 Million USD | -5046.834% |
| Resverlogix Corp. | -11.74 Million USD | -501.277% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -2204.983% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 67.317% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 5901.315% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 897.42% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -4610.235% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 18736.167% |
| AVAX Technologies, Inc. | -6.11 Million USD | -1055.016% |
| Zenith Capital Corp. | -8.6 Million USD | -720.381% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -405169.502% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -2785.883% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -40009.221% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -3575.444% |
| Kadimastem Ltd | -2.62 Million USD | -2590.234% |
| Helix BioMedix, Inc. | -1.04 Million USD | -6647.7% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -38887.675% |
| LadRx Corporation | 412.28 Thousand USD | 17224.645% |
| Cell Source, Inc. | -4.27 Million USD | -1552.465% |
| Regen BioPharma, Inc. | 1.46 Million USD | 4916.106% |
| NovAccess Global Inc. | -1.03 Million USD | -6722.787% |
| Affymax, Inc. | -14.29 Million USD | -393.893% |
| Itoco Inc. | -1.86 Million USD | -3677.538% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -18498.072% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -6226.344% |
| Mobile Lads Corp. | -2.24 Million USD | -3050.245% |
| CytoDyn Inc. | -18.02 Million USD | -291.602% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -89236.826% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -577232.57% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -14436.792% |
| SYBLEU INC | -141.57 Thousand USD | -49770.383% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -6547.96% |
| International Stem Cell Corporation | 202 Thousand USD | 35051.485% |
| Bioxytran, Inc. | -3.82 Million USD | -1748.149% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -134022.34% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -2767.748% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -96.833% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -156793.333% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -2478.598% |
| Neutra Corp. | -181.24 Thousand USD | -38853.472% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -250.226% |
| PureTech Health plc | -11.62 Million USD | -507.225% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -250.25% |
| IXICO plc | -707 Thousand USD | -9886.139% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -818.699% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -46.035% |
| CSL Limited | 4.73 Billion USD | 101.492% |
| Cellectis S.A. | -92.63 Million USD | 23.786% |